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pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where no treatment 
exists, involves the compartmentalization of the nuclear protein TDP-43 (TAR DNA-binding protein 
43) in the cytoplasm which is promoted by its aberrant phosphorylation and others posttranslational 
modifications. Recently, it was reported that CK-1δ (protein casein kinase-1δ) is able to phosphorylate 
TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1δ inhibitor IGS-2.7, both in a TDP-43 
(A315T) transgenic mouse and in a human cell-based model of ALS, is shown. Treatment with IGS-2.7 
produces a significant preservation of motor neurons in the anterior horn at lumbar level, a decrease 
in both astroglial and microglial reactivity in this area, and in TDP-43 phosphorylation in spinal cord 
samples. Furthermore, the recovery of TDP-43 homeostasis (phosphorylation and localization) in a 
human-based cell model from ALS patients after treatment with IGS-2.7 is also reported. Moreover, we 
have shown a trend to increase in CK-1δ mRNA in spinal cord and significantly in frontal cortex of sALS 
cases. All these data show for the first time the in vivo modulation of TDP-43 toxicity by CK-1δ inhibition 
with IGS-2.7, which may explain the benefits in the preservation of spinal motor neurons and point to 
the relevance of CK-1δ inhibitors in a future disease-modifying treatment for ALS.
Amyotrophic Lateral Sclerosis (ALS) is a fatal progressive neurodegenerative disease, which results in the destruc-
tion of upper and/or lower motor neurons in the brain and spinal cord. It usually affects people between 40 and 
60-year-old and the average survival from onset to death is 3–4 years1. Despite the severity of the disease and the 
high health care and social costs, no cure or viable long-term effective treatment has been identified, with only 
two therapeutic agents (riluzole and edaravone) already approved by FDA (Food and Drug Administration) but 
having limited efficacy or serving only for specific groups of patients2.
In 2006, the trans-activating response region DNA binding protein of 43 KDa, known as TDP-43, was iden-
tified as one of the main hallmarks of sporadic and familial ALS, showing accumulations in the cytoplasm of 
cortical and spinal motor neurons3. Mutations in this protein have been associated with cases of ALS (accounting 
for approximately 5% of genetic cases), but also have been associated with tau protein-independent cases of 
frontotemporal dementia (FTD), generating the idea of a pathological spectrum between ALS and FTD based on 
alterations in TDP-43 and other related proteins4. Today, it is recognized that TDP-43 proteinopathy, character-
ized by hyperphosphorylation, truncation, ubiquitination, and/or nuclear depletion in neurons, is the prominent 
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and common pathological feature of sporadic and familiar ALS1. Furthermore, it is present in rare diseases such 
as Perry syndrome or Alexander disease, but also in the prevalent Alzheimer’s disease (AD) and recently in the 
limbic-predominant age-related TDP-43 encephalopathy (LATE)2,3. In addition, TDP-43 pathology is a second-
ary feature of several other neurodegenerative disorders, including Parkinson’s disease (PD), and Huntington’s 
disease (HD), where its presence may aggravate the primary existing proteinopathy4.
The study of the post-translational regulation of TDP-43 has placed the phosphorylation of this protein at 
specific residues, which is dependent on certain protein kinases, as a key event for regulating its cellular activities 
and also for its dysregulation associated with pathological conditions5,6. In fact, phospho-TDP-43 is distributed in 
brain areas of FTD and ALS patients5. Different kinases have been recently involved in TDP-43 phosphorylation. 
Among these, protein casein kinase-1 (CK-1)7, tau tubulin kinase 1 (TTBK1)6 and cell division cycle kinase 7 
(CDC7)7 are the best characterized.
CK-1 was the first kinase identified to phosphorylate TDP-43 in vivo in more than 29 different sites, being 18 
of them located in the C-terminal glycine-rich region7. Moreover, different stress signaling cause CK-1-dependent 
phosphorylation of TDP-43 triggering its cytosolic mislocalization and accumulation8,9. Furthermore, TDP-43 
binds directly to and regulates the expression of CK-1ε mRNA10.
CK-1 is a highly conserved Ser/Thr kinase, constitutively active and ubiquitously expressed in eukaryotic 
organisms, with different human isoforms characterized (α, ɣ1–3,δ and ε)8. It is tightly regulated in cells because 
its role in crucial cellular processes. However, its dysregulation leads to different pathologies including cancer 
and neurodegenerative diseases11. Recently, inhibition of CK-1, mainly the δ and ε isoforms, has been proposed 
as a potential treatment for different neurodegenerative diseases including ALS, FTD9 and Alzheimer’s disease12.
We have discovered and synthetized new families of potent CK-1δ and dual CK-1δ/ε inhibitors with high 
selectivity score over other kinases based on the modification of the benzothiazole scaffold10. They have been 
proven to decreased TDP-43 phosphorylation both in cellular models and in vivo using a Drosophila transgenic 
model11. Moreover, two of these candidates, named as IGS-2.7 and IGS-2.37, have also shown a decrease on 
TDP-43 phosphorylation and nuclear localization using a cell-based model of human lymphoblast from FTD 
patients carrying a progranulin (GRN) mutation12. Therefore, our working hypothesis is that inhibitors of CK-1δ 
able to modulate TDP-43 proteinopathy in vivo, may be a good therapeutic strategy for the severe ALS. We have 
treated the TDP-43 (A315T) transgenic mice, one of the first experimental models of ALS based on mutations 
in TDP-43 protein13, with the brain permeable CK-1 inhibitor IGS-2.7. Our results show, for the first time, an in 
vivo decrease of TDP-43 phosphorylation, together with motor neuron survival and decrease of both astroglial 
and microglial reactivity. Furthermore, using lymphoblasts from sALS patients we have showed the recovery of 
TDP-43 homeostasis (phosphorylation and localization) after the treatment with the CK-1δ inhibitor. Moreover, 
an increase of CSKN1D mRNA in spinal cord and frontal cortex from patients of sporadic ALS (sALS) are also 
shown. All these data may serve as a solid proof of concept for the potential therapy of ALS with CK-1δ or dual 
CK-1δ/ε inhibitors showing a promising neuroprotective effect.
Results
Treatment with IGS-2.7, a CK-1δ inhibitor, in TDP-43 (A315T) transgenic mice. The first objective 
of our study was to explore the effects of a chronic treatment with the compound IGS-2.7 in the TDP-43 (A315T) 
transgenic mouse model. To this end, TDP-43 (A315T) transgenic mice and wild-type animals were daily treated 
with the inhibitor IGS-2.7 or vehicle from the age of 65 days up to 90 days. First, we observed the expected 
progressive decrease in animal weight in TDP-43 (A315T) transgenic mice, which was partially delayed after 
the treatment with IGS-2.7. This effect of IGS-2.7 in transgenic TDP-43 (A315T) mice weight was statistically 
significant from the day 19 of treatment (Fig. 1), although they resulted to be statistically different compared to 
wild-type animals at the last two time-points analysed (23 and 25 days of treatment) (Fig. 1).
We next investigated the effect of IGS-2.7 against the spinal motor neuron degeneration typical of TDP-43 
(A315T) transgenic mice. A reduction in the number of motor neurons was evident in the anterior horn at lum-
bar level by using both Nissl staining and choline acetyl transferase (ChAT) immunohistochemistry (Fig. 2). The 
treatment with IGS-2.7 rescued the loss of both Nissl and ChAT-positive cells in TDP-43 (A315T) transgenic 
mice (Fig. 2), stressing an important neuroprotective effect in this experimental model of ALS.
Glial reactivity and associated inflammatory events have been claimed as important pathogenic players in ALS 
neurodegeneration14. We investigated the effect of this treatment on astroglial and microglial reactivity labelled by 
GFAP and Iba-1 immunostaining, respectively. TDP-43 transgenic mice showed statistically significant elevations 
in both microglial and astrocyte immunoreactivities compared to wild-type animals, whereas the treatment with 
IGS-2.7 completely blocked the elevated immunoreactivity of microglial cells and partially reduced the immuno-
reactivity of astrocytes compared to the controls (Fig. 2).
It is believed that abnormal phosphorylation of TDP-43 is a critical step of FTD-TDP and ALS15. On these 
grounds, we investigated whether our CK-1δ inhibitor IGS-2.7 chronic treatment could prevent the enhanced 
TDP-43 phosphorylation in vivo in these transgenic mice. To this end, we analysed the levels of both phospho-
rylated and total TDP-43 in spinal cord samples of TDP-43 (A315T) transgenic mice and wild-type animals by 
immunoblotting with specific antibodies. We observed a robust increase in the ratio of pTDP-43/TDP-43 in TDP-
43 (A315T) transgenic mice compared with wild-type animals (Fig. 3), which was completely reversed, at values 
similar to wild-type animals, by the treatment with IGS-2.7 (Fig. 3).
Lastly, it is important to remark that the positive effects of IGS-2.7 in maintaining animal weight, preserving 
spinal motor neurons and limiting glial reactivity were exclusively found in TDP-43 transgenic mice treated with 
the inhibitor causing no effects when is administered to wild-type animals (Figs. 1–3).
Effect of IGS-2.7 on TDP-43 phosphorylation of lymphoblasts from control and sporadic ALS 
individuals. Previous work from our laboratory demonstrated that lymphoblasts derived from FTD and ALS 
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patients, easily available, could represent a suitable platform to search novel disease-modifying drugs16,17. For this 
reason, we decided to explore the biological profile of IGS-2.7 on lymphoblasts derived from sALS patients. The 
effect of IGS-2.7 in decreasing TDP-43 phosphorylation in control and sALS cells was assessed by Western blot-
ting using a phospho-specific (S409/410) and anti-TDP-43 antibodies at two different compound concentrations. 
Figure 4 shows a representative immunoblot. Levels of phospho-TDP-43 were higher in sALS samples than in 
controls (healthy individuals), mimicking this pathological hallmark of ALS pathology. Treatment of lympho-
blasts with 5 µM of IGS-2.7 for 24 h, resulted in a significant decrease in the levels of phosphorylation of TDP-43 
in sALS lymphoblasts while no differences were observed in controls.
Next, we addressed whether the treatment of IGS-2.7 on ALS lymphoblasts could normalize the mislocalization of 
TDP-43, thus recovering the TDP-43 homeostasis. Subcellular distribution of TDP-43 was assessed by immunostaining 
using a phospho-independent anti-TDP-43 antibody. Figure 5 shows how IGS-2.7 treatment prevented the cytosolic 
accumulation of TDP-43 in lymphoblasts from ALS patients with no effects on control cells.
CK-1 expression in human spinal cord of control and sporadic ALS patients. To assess whether 
CK-1δ promotes TDP-43 phosphorylation in ALS patients, we analysed the expression levels of CSNK1D and 
CSNK1E genes and the kinase abundance of CK1 in spinal cord of control and sporadic ALS patients. Figure 6a 
shows the expression levels of CSNK1D and CSNK1E mRNA in the anterior horn of the spinal cord and frontal 
cortex area 8 in sALS cases. A tendency to increase of CSNK1D mRNA levels was observed in the anterior horn 
of spinal cord (p = 0.07) in sALS cases when compared with controls (Fig. 6a). Significant increase in CSNK1D 
mRNA levels occurred in frontal cortex of sALS cases when compared with controls (p = 0.025) (Fig. 6b). In con-
trast, no significant differences in CSNK1E mRNA levels were seen between control and sALS cases.
Immunohistochemistry for CK-1δ was performed thereafter in human spinal cord sections of 6 control and 
sporadic ALS cases. Figure 6C demonstrates diffuse CK-1δ immunoreactivity in the cytoplasm in both motor 
neurons from ALS and control cases with the exception of apparent increased immunoreactivity in shrunken 
neurons. Since the number of motor neurons was decreased in ALS cases, the amount of neuronal CK-1δ immu-
noreactivity was lower in ALS when compared with controls. However, increased CK-1δ immunoreactivity was 
observed in reactive glial cells in the anterior horn of ALS cases (Fig. 6C, right panel).
Discussion
ALS is a fatal motor neurodegenerative disorder devoid of an effective therapy. The development of innovative 
drugs displaying neuroprotective and anti-inflammatory activities that might delay disease onset, slow its pro-
gression and/or prolong survival is a major therapeutic goal in ALS disorder. Deposition of intracellular aggre-
gates of phosphorylated TDP-43 is a hallmark lesion in almost all cases of ALS, as well as in FTD8. Since TDP-43 
protein plays an important role in RNA metabolism, apoptosis, cell division and plasticity13,18–21, it is likely that 
TDP-43 aggregation can promote neurodegeneration22. Therefore, strategies that prevent TDP-43 misfolding, 
aggregation and/or enhance clearance of pathological TDP-43 may serve as an important neuroprotective mech-
anism to counteract disease progression in ALS. With this purpose, we have explored here the therapeutic poten-
tial of inhibiting one of the key protein kinases involved in TDP-43 phosphorylation, protein kinase CK-1δ. We 
have tested the effectiveness of the brain permeable small molecule named as IGS-2.7, a potent inhibitor of CK-1δ 
with some residual inhibitory activity on CK-1ε, in an in vivo preclinical study using a TDP-43 transgenic mice 
Figure 1. In vivo experiment with IGS-2.7. (a) Chemical structure of IGS-2.7 and its IC50 values on CK-1. (b) 
Experimental design of i.p. administration of the compound IGS-2.7 (c) Effects of IGS-2.7 treatment on body 
weight gain in TDP-43 and wild-type mice. Values are expressed as means ± SEM; N ≥ 8 animals in each group. 
Data were assessed by repeat measures two-way ANOVA followed by the Bonferroni test (*p < 0.05, **p < 0.01, 
***p < 0.001 vs. WT-Veh group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. TDP-43-Veh).
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model of ALS. It is important to remark that it is the first attempt to investigate a pharmacological treatment 
based on kinase inhibition in this mouse model of ALS. Moreover, we have extended our study to lymphoblasts 
from sporadic ALS patients, as we have shown the versatility of this human-cell based assay for drug discovery 
programs including FTD23.
Figure 2. Photomicrographs of histological samples in the anterior horn of the spinal cord of TDP-43 mice 
and wild-type controls. (a) Representative images of Nissl staining of motor neurons (black arrows), ChAT, 
Iba-1 and GFAP immunostained sections (b) Quantification of the different markers. Total average number of 
motor neurons (Nissl, ChAT+), microglia (Iba-1+) and astrocytes (GFAP+) is shown. Data are expressed as 
a percentage over the WT-Veh group. Values are expressed as means ± SEM, N ≥ 6 in each group. Data were 
assessed by one-way ANOVA followed by the Bonferroni test (*p < 0.05, **p < 0.01, ***p < 0.001 vs. WT-Veh 
group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. TDP-43-Veh). Scale bars = 200 μm.
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Our results, shown that a chronic treatment with the compound IGS-2.7 effectively prevents the phosphoryl-
ation of TDP-43 in vivo in the spinal cord of TDP-43 transgenic mice, being this effect associated with an atten-
uation of most of the events that reflect the worsening of the pathological phenotype. This chronic treatment has 
no effect in the healthy animal (wild-type), despite the fact that CK1-δ is constitutively expressed. It seems that 
IGS-2.7 selectively prevents the aberrant hyperphosphorylation found in the transgenic TDP-43 mice. Whether 
the overactivation of CK-1δ in pathological conditions, is due to changes in mRNA, protein expression levels, 
posttranslational modifications, or in the sequestration of the enzyme in subcellular compartments24 remains 
to be elucidated. Among the pathological events ameliorated by CK-1δ inhibitor treatment, IGS-2.7 attenuated 
the typical animal weight losses, prevented the death of spinal motor neurons and reversed the glial reactivity 
affecting both microglial cells and especially astrocytes, which are particularly abundant in this experimental 
model. All these data strongly suggest that the inhibition of CK-1δ with the benzothiazole derivative IGS-2.7 may 
modulate TDP-43 toxicity in vivo by limiting TDP-43 phosphorylation, which situates this event in a key position 
to explain the benefits observed with this drug candidate in the preservation of spinal motor neurons. It is true 
that the recovery of these parameters is not complete but partial, which stresses the need to better optimize this 
treatment, either by elevating the active dose used or by combining IGS-2.7 with another neuroprotective agent 
(e.g riluzole). Furthermore, these rescued motor neurons should be involved in the muscular junction as choline 
acetyl transferase (ChAT) immunohistochemistry, an enzyme responsible for the synthesis of the neurotransmit-
ter acetylcholine, is used in their quantification25.
Moreover, we used lymphoblastoid cell lines derived from sALS patients to mimic the central nervous system 
(CNS) dysfunction and investigated the effect of IGS-2.7 on TDP-43 pathology. Lymphoblasts from patients 
may reflect changes occurring in the CNS and represent a novel, easily accessible human-based cell model for 
drug screening and investigation23. Recently, we have shown that immortalized lymphocytes from sporadic ALS 
patients recapitulate pathological TDP-43 features17. Here, we report that treatment with the CK-1δ IGS-2.7 
inhibitor improved TDP-43 homeostasis in this human cell-based sALS model. Benzothiazole IGS-2.7 not only 
decreases TDP-43 phosphorylation in cells derived from ALS patients but also corrects the subcellular localiza-
tion of TDP-43, preventing the abnormal cytosolic TDP-43 accumulation in ALS lymphoblasts. This finding is 
in consonance with a previous work in which the effect of IGS-2.7 on the subcellular localization of TDP-43 was 
additionally evaluated in fractionated nuclear and cytoplasmic extracts from FTD-derived lymphoblasts16.
Finally, and in order to enhance the translational value of the results found in the in vivo model, we analysed 
the expression of CK-1δ and CK-1ε in the anterior horn of the spinal cord and frontal cortex area 8 in healthy 
subjects and sALS patients by quantitative RT-PCR. We have found a tendency to increase in the mRNA levels of 
CSNK1D in the anterior horn of the spinal cord and a significant increase in the frontal cortex area 8. In contrast, 
no differences in CSNK1E expression were found in the spinal cord and frontal cortex in sALS when compared 
with controls. Moreover, we analysed CK-1δ immunoreactivity in the anterior horn of spinal cord in control and 
ALS cases. CK-1δ expression was present in the cytoplasm of motor neurons of anterior horn without differences 
between control and ALS cases, with the exception of apparent increased immunoreactivity in shrunken neu-
rons. However, we observed increased CK-1δ immunoreactivity in reactive glial cells in the anterior horn of ALS 
cases. This increase was not observed in control samples. These observations suggest the involvement of CK-1δ 
in human ALS pathology. The selective immunoreactivity of CK-1δ found in ALS reactive glial cells may also well 
correlate with the in vivo effect observed after the treatment with IGS-2.7 of reversion of the glial reactivity both 
in microglial cells and especially astrocytes.
In conclusion, our results show strong evidence to support that IGS-2.7 has neuroprotective properties, derived 
from its capability to reduce the phosphorylation of TDP-43. This has been seen in vivo, in TDP-43 mouse model, in 
which the inhibitor preserved motor neurons in ventral horn of spinal cord, and also in vitro using a human cell-based 
ALS model (lymphoblasts derived from sALS patients). In that model, IGS-2.7 treatment recovers TDP-43 homeostasis 
by decreasing its phosphorylation and enhancing the nuclear localization. Moreover, up-regulation of CK-1δ is shown 
Figure 3. Effects of IGS-2.7 on phosphorylation of TDP-43 in the spinal cord of wild-type and transgenic TDP-
43 mice. (a) Spinal cord lysates from wild-type and transgenic TDP-43 mice were used to determine the levels of 
pTDP-43 and TDP-43. (b) Representative immunoblots are shown. Densitometric analyses represent the ratio 
of pTDP-43/total TDP-43 and are the mean ± SEM of 8 observations per group. Data were assessed by one-way 
ANOVA followed by the Bonferroni test (*p < 0.05 WT-Veh group; #p < 0.05 vs. TDP-43-Veh).
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in brain (frontal cortex) and spinal cord of sALS patients. Altogether, our results indicate that the inhibition of CK-1δ 
with selective inhibitors, specifically with the benzothiazole derivative IGS-2.7 used here, might represent a good ther-
apeutic approach for disorders involved in TDP-43 protein alterations including ALS and FTD, among others. Only 
future clinical studies can confirm these results in patients. Moreover, it is worth mentioning that this CK-1δ inhibitor 
does not produce mutations, which makes it a good candidate for future pharmaceutical development26. Only future 
clinical trials will be able to confirm these results in patients.
Methods
All reagents for cell culture assays were obtained from Invitrogen (Carlsbad, CA, USA). For Western blots (WB) 
experiments, PVDF (polyvinylidene difluoride) membranes were obtained from Bio-Rad (Richmond, CA, USA). 
Chemiluminescent reagent (ECL) for WB detection was purchased from Amersham (Uppsala, Sweden). All other 
reagents were of molecular grade. The N-benzothiazolyl-2-phenyl-acetamides derivative, CK-1δ inhibitor, IGS-
2.7 was synthesized as previously described27 in our laboratory. Antibodies against human TDP-43 (10782-2-AP) 
and phospho (Ser409/410)-TDP-43 (22309-1AP) were purchased from Proteintech (Manchester, UK). Antibodies 
against α-tubulin (sc-23948), and GAPDH (sc-25778) were obtained from Santa Cruz Biotechnologies (Santa 
Cruz, CA, US), anti-GFAP antibody was obtained from DAKO (Glostrup, Denmark), anti-Iba-1 (019-19741) was 
purchased in Wako Chemicals (Richmond, VI, USA), and anti-ChAT antibody (PA5-29653) was obtained from 
Life Technologies (Carlsbad CA, US). Dilutions are shown in Table 1.
Animal procedures. Prp-hTDP-43(A315T) transgenic mice and non-transgenic littermate sibling were used 
as model in all the experiments. Mice were breeding in our animal facilities from initial breeders were purchased 
to Jackson Laboratories (Bar Harbor, ME, USA).
Offspring were genotyped for the TARDBP transgene which contain the A315T mutation following a proce-
dure described previously13. Mice were housed in an environment with controlling temperature (22 ± 1 °C) and 
light (12-h light/dark cycle) with food and water available ad libitum. Experimental designs and procedures were 
approved by the ethical committees of the Complutense University and the regulatory institution (ref. PROEX 
059/16) in accordance with the European Commission regulations (2010/63/EU) for the use of laboratory ani-
mals. Then, once genotyped, wild-type and transgenic mice were identified by numbered earmarks and, prior to 
the start of the different experiments, they were randomly allocated to the different treatment groups. For data 
collection, in all behavioral and histological analyses, researchers were blinded to the animal treatment, whereas 
for the biochemical analyses, due to the form in which the data are collected, blinding was not considered neces-
sary, as previously described28.
Lymphoblastic cell lines. Peripheral blood samples from 4 sALS patients and 4 age-matched control sub-
jects were used for peripheral blood mononuclear cells (PBMCs) isolation on Lymphoprep™ density-gradient 
centrifugation according to the instructions of the manufacturer (Axis-Shield Po CAS, Oslo, Norway). 
Establishment of lymphoblastoid cell lines was performed in our laboratory by infecting peripheral blood lym-
phocytes with the Epstein–Barr virus as described previously29. All patients were diagnosed by applying the 
revised El Escorial criteria30 in the Hospital Doce de Octubre (Madrid, Spain). All procedures were approved by 
the Hospital Doce de Octubre and the Spanish Council of Higher Research Institutional Review Board and are 
in accordance with National and European Union Guidelines. Informed written consent was obtained from all 
the participants. Demographic and clinic characterization of individuals enrolled in this study can be found in 
Table 2.
Figure 4. Effect of IGS-2.7 on TDP-43 phosphorylation in immortalized lymphocytes from control and 
sporadic ALS individuals. Immortalized lymphocytes were seeded at an initial density of 1 × 106 × ml−1 in 
absence or presence of IGS-2.7 (2.5 and 5 μM). 24 h after drugs addition, cells were harvested and processed for 
Western blotting analysis. (a) Densitometric measurements were performed on individual immunoblots and 
values indicate the mean of p-TDP-43 versus the corresponding total TDP-43 levels ± SEM for experiments 
carried out with 4 different cell lines for each group. (b) Representative immunoblot is shown. Data were 
assessed by one-way ANOVA and post hoc Fisher’s analysis (***p < 0.001 significantly different from control 
cells; ##p < 0.01 and significantly different from untreated ALS cells).
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Lymphoblastoid cells lines were grown in suspension in T flasks in an upright position, in approximately 8 ml 
of RPMI-1640 medium that contained 2 mM L-glutamine, 100 μg/ml streptomycin/penicillin and 10% (v/v) fetal 
bovine serum and maintained in a humidified 5% CO2 incubator at 37 °C. Fluid was routinely changed every 
three days by removing the medium above the settled cells and replacing it with an equal volume of fresh medium 
as previously described17.
Figure 5. Subcellular localization of TDP-43 after IGS-2.7 treatment of lymphoblasts from control and ALS 
subjects. Lymphoblasts were seeded at 106 cells × ml−1 and incubated in presence or absence of IGS-2.7 (5 μM) 
for 24 h. (a) Cells were stained with anti-TDP-43 antibody followed by a secondary antibody labeled with Alexa 
Fluor 488. DAPI was included in the mounting media to stain the nucleus. TDP-43 protein localization was 
assessed by confocal laser scanning microscopy. Merged images show that treatment with IGS-2.7 prevented the 
higher cytosolic accumulation (red arrows) of TDP-43 protein in ALS patients. Scale bars = 11 μM. Magnified 
cells from images are shown on the right panels for better visualization (Scale bars = 3 μm) (b) Quantification 
of TDP-43 cytosolic localization in lymphoblasts from ALS patients compared to controls. Data are expressed 
as mean ± SEM for experiments carried out with 4 different cell lines for each group. Data were assessed by 
one-way ANOVA and post hoc Fisher’s analysis (**p < 0.01 from control cells; ###p < 0.001 from untreated ALS 
cells).
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Treatments and sampling. TDP-43 (A315T) transgenic male mice and wild-type mice were used to reg-
ister disease progression and spinal cord decline in a pharmacological study using the CK-1δ inhibitor, IGS-2.7. 
This compound was synthetized in our laboratory following described procedures showing an IC50 value for 
CK-1δ of 23 nM and a residual IC50 of 840 nM for CK-1ε27. Mice (10 per group) were treated starting at the age of 
65 days old, intraperitoneally, with IGS-2.7 (1 mg/kg of body weight) in 6.2% Tween 20 and 4% DMSO in saline 
buffer daily until sacrifice at the age of 90 days old. The rationale for this range of age has been explained in several 
studies28,31 based on the fast progression of this model compared to other TDP-43-based model32. Vehicle injec-
tions were administered to control animals. This dose was selected based on previous pharmacokinetic results 
of compound IGS-2.7, that shows good levels of the drug in plasma and brain after intraperitoneally and oral 
administration16. During all the treatment, we also recorded the physical appearance and the animal weight gain.
As we described previously28, after 25 days of chronic treatment, TDP-43(A315T) transgenic male mice and 
their corresponding wild-type animals were euthanized 24 h after the last injection of IGS-2.7 by decapitation and 
their spinal cords were dissected and rapidly removed. The spinal samples to be used for western blot analyses 
Figure 6. Relative expression of CSNK1D and CSNK1E mRNA levels in post-mortem samples from control 
and ALS subjects and immunohistochemical analysis. (a) CSNK1D and CSNK1E mRNA levels in the 
anterior horn of the spinal cord and (b) frontal cortex area 8 of sALS cases and controls, *p < 0.05. (c) CK-1δ 
immunoreactivity in the anterior horn of the spinal cord at lumbar level in control and ALS cases showing 
CK-1δ immunoreactivity in the cytoplasm of neurons and neuronal processes in control. Similar reaction is 
found in the remaining motor neurons in devastated anterior horn in the ALS case together with increased 
CK-1δ immunoreactivity in reactive glial cells (arrows). Paraffin sections, slightly counterstained with 
haematoxylin; scale bar = 25 µm.
Antibody name Company Dilution
ChAT (PA5-29653) Life Technologies 1:200
Iba-1 (019-19741) Wako Chemicals 1:500
GFAP (Z0334) DAKO 1:500
β-actin (sc-81178) Santa Cruz 1:500
Human TDP-43 (10782-2-AP) Proteintech 1:1000
Human Ser409/410TDP-43 (22309-1AP) Proteintech 1:500
α-tubulin (sc-23948) Santa Cruz 1:1000
GAPDH (sc-25778) Santa Cruz 1:500
Alexa Fluor 488 (R37118) Life Technologies 1:200
CK-1δ AbCam 1:100
Table 1. Summary of antibodies used.
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were frozen in 2-methylbutane cooled in dry ice and stored at −80 °C. The spinal samples to be used for his-
tological analyses were fixed for one day at 4 °C in fresh 4% paraformaldehyde prepared in 0.1 M phosphate 
buffered-saline, pH 7.4. Samples were then cryoprotected by immersion in a 30% sucrose solution for a further 
day, and finally stored at −80 °C. Fixed spinal cords were sliced with a cryostat at the lumbar level (L4-L6) to 
obtain coronal sections (20 μm thick) that were collected on gelatine-coated slides. Sections were used for proce-
dures of Nissl-staining and immunofluorescence.
Histological procedures. Nissl staining. Sections of the spinal cord at the lumbar level (L4-L6) were used 
for Nissl staining following the protocol previously described28. We used cresyl violet 0.25% with 0.1% of acetic 
acid. Slices were dehydrated by an increased ethanol concentration series, sealed and cover-slipped with the 
non-aqueous mounting medium DPX (Sigma-Aldrich, San Luis, MI, USA). A Leica DMRB microscope (Leica, 
Wetzlar, Germany) and a Leica DFC300FX camera were used for slice observation and for taking photographs of 
the tissues. The number of total motor neurons in the ventral horn was counted in at least six slices to a minimum 
of 6 animals per experimental group. To count the number of stained motor neurons (>400 μm2) in the ventral 
horn, high resolutions photomicrographs were taken with a 10X objective under the same conditions of light, 
brightness and contrast. The final value for each group is the mean of all animals included in the study.
Immunofluorescence. Slices from TDP-43 (A315T) mice model and controls were used for immunofluores-
cence study. The protocol used was as described previously28. Tissue sections were pre-incubated for 1 h with 
Tris-buffered saline with 1% Triton X-100 (pH 7.5) for permeabilization. Then, sections were incubated overnight 
at 4 °C with a polyclonal anti-ChAT (1:200; Life Technologies, CA, USA), anti-Iba-1 (1:500; Wako Chemicals, 
Richmond, VI, USA) or anti GFAP (1:500; DAKO, Glostrup, Denmark) antibody. After several washes with 
Tris-buffered saline, tissues were incubated with an Alexa 488 secondary antibody conjugate (1:200; Life 
Technologies) for 2 h at 37 °C. For slice observation and photography, a Leica DMRB microscope and a Leica 
DFC300FX camera were used. Quantification of immunofluorescence was carried out on high-resolution photo-
micrographs that were taken with the 10X objective, under the same conditions of light, brightness and contrast. 
The software of analysis Image J (NIH; Bethesda, MD, USA) was used to quantify the mean density of labelling in 
a selective area. Six sections coming from at least six animals were analysed to establish the mean value for each 
group included in the study. The final data were normalized and were expressed relative to wild-type animals. 
Subcellular localization of TDP-43 was assessed in human lymphoblasts by immunofluorescence as previously 
described17. Cells (1 × 106 ml−1) were incubated with and without IGS-2.7 (5 µM) for 24 h and then fixed for 
30 min in 4% paraformaldehyde in PBS and blocked and permeabilized with 0.5% TritonX-100 in PBS-0.5% 
BSA for 60 min at room temperature. Cells were attached to poly-L-lysine coated coverslips using the Cytospin 
centrifuge at 700 rpm for 7 minutes before they were incubated overnight with the anti-TDP-43 polyclonal anti-
body. After removing the primary antibody, cells were washed with PBS and were incubated with Alexa Fluor 
488-conjugated anti-rabbit antibody. Preparations were mounted on ProLong® Gold Antifade Reagent with 
DAPI (Thermo Fisher) allowing nuclear visualization. High-resolution images were acquired for ∼30 cells per 
group in n = 4 independent experiments using a confocal microscope Zeiss 510 equipped with a META detection 
system and a 63x oil immersion objective. Cytosolic TDP-43 levels per cell were quantified using the Volocity 
software (PerkinElmer, Waltham, MA, USA).
Tissue sections from 6 ALS cases and 6 age-controls were used for immunostaining study. Formalin-fixed, 
paraffin-embedded, de-waxed 4 µm-thick sections of human anterior horn of the spinal cord at the level of upper 
lumbar were boiled in citrate buffer for 20 min to retrieve protein antigenicity. Endogenous peroxidases were 
blocked by incubation in 10% methanol and 1% H2O2 for 15 min, followed by 3% normal horse serum incuba-
tion and washed in distilled water. The sections were incubated at 4 °C overnight with the mouse monoclonal 
anti-CK-1δ antibody (Abcam, Cambridge, UK) used at a dilution of 1:100. Following incubation with the primary 
antibody, the sections were incubated with EnVision+ system peroxidase (Dako, Agilent Technologies, Santa 
Clara, CA, USA) for 30 min at room temperature. The peroxidase reaction was visualized with diaminobenzidine 
and H2O2. Control of the immunostaining included omission of the primary antibody and no signal was obtained 
following incubation with only the secondary antibody. Finally, the sections were slightly counterstained with 
haematoxylin.
Immunoblotting analysis. Samples of spinal cords from TDP-43 (A315T) mice and controls were used to 
assess TDP-43 phosphorylation state as previously described33.
CONTROL ALS
(n = 4) (n = 4)
Gender (M/F) (1/3) (1/3)
Family history No No
Age (y ± SD) 62 ± 9 68 ± 9
Site of onset (n)
Bulbar NA 4
Table 2. Demographic and clinical characterization of subjects included in this study. M: male; F: female; y: 
years. 
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Mouse spinal cords were lysed in RIPA buffer supplemented with a protease and phosphatase inhibitor cock-
tail (Roche, Mannhein, Germany). To prepare whole-cell extract, cells were harvested, washed in PBS and then 
lysed in ice-cold lysis buffer as described. The protein content of the extracts was determined by the Pierce BCA 
Protein Assay kit (Thermo Scientific). 20–50 μg of protein were fractionated on SDS poly-acrylamide gel and 
transferred to poly-vinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes 
were then blocked with 5% bovine serum albumin (BSA) (Sigma) for 1 h and then incubated overnight at 4 °C, 
with primary antibodies at the dilutions indicated in Table 1. Signals from the primary antibodies were amplified 
using species-specific antisera conjugated with horseradish peroxidase (Bio-Rad) and detected with a chemilu-
minescent substrate detection system ECL. Protein band densities were quantified using a ChemiDoc station with 
Quantity One 1D analysis software (Bio-Rad Laboratories, Madrid, Spain). All the immunoblots can be found in 
the supplementary data file.
Human cases. Post-mortem fresh-frozen lumbar spinal cord (SC) and frontal cortex (FC) (Brodmann area 8) 
samples were obtained from the Institute of Neuropathology HUB-ICO-IDIBELL Biobank following the guide-
lines of Spanish legislation on this matter (Real Decreto 1716/2011) and approval of the local ethics commit-
tee of the Bellvitge University Hospital-IDIBELL. The post mortem delay varied from 2 hours and 15 minutes to 
17 hours. One hemisphere was immediately cut in coronal sections, and selected areas of the encephalon were 
rapidly dissected, frozen on metal plates over dry ice, placed in individual labeled air-tight plastic bags, and 
stored at −80 °C until use for biochemical studies. The other hemisphere was fixed by immersion in 4% buffered 
formalin for no less than 3 weeks for morphological studies. The lumbar anterior spinal cord was dissected on 
a dry-ice frozen plate under a binocular microscope at a magnification x4. Cases with concomitant pathologies 
were not considered in the present study. The series included 18 sALS cases and 30 controls. The anterior horn 
of the spinal cord was available in 14 sALS (mean age 57 years; 6 men and 8 women) and the frontal cortex area 
8 in 15 sALS (mean age 54 years; 11 men and 4 women). The spinal cord and frontal cortex were available in 11 
cases34. Mutations related to ALS and/or FTD, including SOD1, C9ORF72, TARDBP and FUS, were excluded in 
every case. Age-matched control cases had not suffered from neurologic and psychiatric disorders and did not 
show alterations34.
RNA extraction and RT-qPCR validation. RNA from frozen spinal cord and frontal cortex area 8 was 
extracted following the instructions of the supplier (RNeasy Mini Kit, Qiagen® GmbH, Hilden, Germany). 
RNA integrity and 28S/18S ratios were determined with the Agilent Bioanalyzer (Agilent Technologies Inc, 
Santa Clara, CA, USA) to assess RNA quality, and the RNA concentration was evaluated using a NanoDrop™ 
Spectrophotometer (Thermo Fisher Scientific). Complementary DNA (cDNA) preparation used High-Capacity 
cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) following the protocol provided by 
the supplier. Parallel reactions for each RNA sample run in the absence of MultiScribe Reverse Transcriptase to 
assess the lack of contamination of genomic DNA. TaqMan RT-qPCR assays were performed in duplicate for each 
gene on cDNA samples in 384-well optical plates using an ABI Prism 7900 Sequence Detection system (Applied 
Biosystems, Life Technologies, Waltham, MA, USA). For each 10 μL TaqMan reaction, 2.25 μL cDNA was mixed 
with 0.25 μL 20x TaqMan Gene Expression Assays and 2.50 μL of 2x TaqMan Universal PCR Master Mix (Applied 
Biosystems). Relative expression of casein kinase 1 isoform delta (CSNK1D) and epsilon (CSNK1E) genes was 
assessed using the following TaqMan probes: Hs01095996_m1 and Hs01017895_m1, respectively. The values of 
glucuronidase Beta (GUS-β) gene (Hs00939627_m1) were used as internal controls for normalization of fron-
tal cortex samples34 and Hypoxanthine Phosphoribosyl transferase 1 (HPRT-1), (Hs02800695_m1) values were 
used as internal controls34 for normalization of spinal cord samples. The parameters of the reactions were 50 °C 
for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Finally, capture of all TaqMan 
PCR data used the Sequence Detection Software (SDS version 2.2.2, Applied Biosystems). The double-delta cycle 
threshold (ΔΔCT) method was used to analyse the data; and statistical study was performed using T-student test. 
The significance level was set at *p < 0.05, **p < 0.01 and ***p < 0.001 vs. control group34.
Statistical analysis. Data are expressed as mean values ± SEM and statistical analysis was performed using 
the Graph Pad software (version 6.0). Significant differences between the groups were evaluated using two-way 
ANOVA test followed by a Bonferroni post hoc comparison. A p-value lower than 0.05 was used as the limit for 
statistical significance. The sample sizes used in the different experimental groups of all experiments were always 
>5. One-way ANOVA was used to investigate differences between lymphoblasts incubated in the absence or 
presence of IGS2.7.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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